Associations between CYP2E1 promoter polymorphisms and plasma 1,3-dimethyluric acid/theophylline ratios

European Journal of Clinical Pharmacology

Volumn 62, Issue 8, 2006, Pages 627-631

  Yoon, Yeomin ^a   Park, Hyung Doo ^b   Park, Kyoung Un ^b,c   Kim, Jin Q ^b   Chang, Yoon Seok ^b,c   Song, Junghan ^b,c  

^a Konkuk University School of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

1,3 dimethyluric acid; CYP2E1; Metabolism; Polymorphisms; Promoter; Theophylline

Indexed keywords

1,3 DIMETHYLURIC ACID; CYTOCHROME P450 2E1; THEOPHYLLINE;

ARTICLE; CONTROLLED STUDY; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC LINKAGE; GENETIC POLYMORPHISM; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; KOREA; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; METABOLIC CLEARANCE RATE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RANK SUM TEST; TANDEM MASS SPECTROMETRY;

ALLELES; ASTHMA; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2E1; GENOTYPE; HUMANS; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; THEOPHYLLINE; URIC ACID;

EID: 33746423075     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0165-4     Document Type: Article

References (18)

1. Evans WV (1986) Slow release theophylline in chronic bronchitis-a comparative study. Br J Clin Pract 40:245-250
2. Shannon M (1999) Life-threatening events after theophylline overdose: a 10-year prospective analysis. Arch Intern Med 159:894-989
3. Ogilvie RI (1977) Clinical pharmacokinetics of theophylline. Clin Pharmacokinet 3:267-293
4. Gu L, Gonzalez FJ, Kalow W, Tang BK (1992) Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 2:73-77
5. Jennings TS, Nafziger AN, Davidson L, Bertino JS Jr (1993) Gender differences in hepatic induction and inhibition of theophylline pharmacokinetics and metabolism. J Lab Clin Med 122:208-216
6. Song J, Park KU, Park HD, Yoon Y, Kim JQ (2004) High-throughput liquid chromatography-tandem mass spectrometry assay for plasma theophylline and its metabolites. Clin Chem 50:2176-2179
7. Umeno M, McBride OW, Yang CS, Gelboin HV, Gonzalez FJ (1988) Human ethanol-inducible P450IIE1: complete gene sequence, promoter characterization, chromosome mapping, and cDNA-directed expression. Biochemistry 27:9006-9013
8. Hayashi S, Watanabe J, Kawajiri K (1991) Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem (Tokyo) 110:559-565
9. Hanioka N, Tanaka-Kagawa T, Miyata Y, Matsushima E, Makino Y, Ohno A, Yoda R, Jinno H, Ando M (2003) Functional characterization of three human cytochrome P450 2E1 variants with amino acid substitutions. Xenobiotica 33:575-586
10. Danko IM, Chaschin NA (2005) Association of CYP2E1 gene polymorphism with predisposition to cancer development. Exp Oncol 27:248-256
11. Obase Y, Shimoda T, Kawano T, Saeki S, Tomari SY, Mitsuta-Izaki K, Matsuse H, Kinoshita M, Kohno S (2003) Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma. Clin Pharmacol Ther 73:468-474
12. Wan J, Shi J, Hui L, Wu D, Jin X, Zhao N, Huang W, Xia Z, Hu G (2002) Association of genetic polymorphisms in CYP2E1, MPO, NQO1, GSTM1, and GSTT1 genes with benzene poisoning. Environ Health Perspect 110:1213-1218
13. Thompson EA, Deeb S, Walker D, Motulsky AG (1988) The detection of linkage disequilibrium between closely linked markers: RFLP at the AI-CIII apolipoprotein genes. Am J Hum Genet 42:113-124
14. Watanabe J, Hayashi S, Kawajiri K (1994) Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5′-flanking region. J Biochem (Tokyo) 116:321-326
15. Le Marchand L, Wilkinson GR, Wilkens LR (1999) Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone. Cancer Epidemiol Biomarkers Prev 8:495-500
16. Kato S, Tajiri T, Matsukura N, Matsuda N, Taniai N, Mamada H, Yoshida H, Kiyam T, Naito Z (2003) Genetic polymorphisms of aldehyde dehydrogenase 2, cytochrome p450 2E1 for liver cancer risk in HCV antibody-positive Japanese patients and the variations of CYP2E1 mRNA expression levels in the liver due to its polymorphism. Scand J Gastroenterol 38:886-893
17. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, Chang FY, Lee SD (2003) Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37:924-930
18. Tanigawara Y, Komada F, Shimizu T, Iwakawa S, Iwai T, Maekawa H, Hori R, Okumura K (1995) Population pharmacokinetics of theophylline. III. Premarketing study for a once-daily administered preparation. Biol Pharm Bull 18:1590-1598